I-Flow Announces ON-Q Therapy Upheld as Best Practice for Post-Surgical Pain Relief in Pivotal Study.Independent Large-Scale Meta-Analysis Results Published in Prestigious Surgical Journal LAKE FOREST, Calif. -- I-Flow Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :IFLO) announced today that a landmark meta-analysis confirming the efficacy of continuous wound catheters delivering local anesthetic local anesthetic n. An agent that, when applied directly to mucous membranes or when injected about the nerves, produces loss of sensation by inhibiting nerve excitation or conduction. , including ON-Q, for post surgical analgesia analgesia /an·al·ge·sia/ (an?al-je´ze-ah) 1. absence of sensibility to pain. 2. the relief of pain without loss of consciousness. (pain relief) was published in the December 2006 Journal of the American College of Surgeons This article or section needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. (JACS JACS Journal of the American Chemical Society JACS Joint Academic Coding System JACS Journal of the American College of Surgeons JACS Journal of the American Ceramic Society JACS Joint Automated CEOI System (US DoD) ). The large-scale study encompassed 44 different randomized clinical trials randomized clinical trial, n a clinical study where volunteer participants with comparable characteristics are randomly assigned to different test groups to compare the efficacy of therapies. which included 2,141 patients across a wide range of surgical procedures. JACS is a prominent peer-reviewed journal peer-reviewed journal Refereed journal Academia A professional journal that only publishes articles subjected to a rigorous peer validity review process. Cf Throwaway journal. that is the official scientific publication of the American College of Surgeons. The authors, from three world-class medical centers cited in the study, Cornell University, The Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. and Virginia Mason Medical Center Virginia Mason Medical Center (VMMC), founded in 1920, is a private, non-profit organization located on Seattle, Washington's First Hill offering a system of integrated health services. Gary S. Kaplan, MD, serves as chairman and CEO, and J. , are encouraging widespread clinical use of the therapy. They arrived at this conclusion because their study compiled patient outcomes with continuous local anesthetic therapy as compared to narcotics narcotics n. 1) techinically, drugs which dull the senses. 2) a popular generic term for drugs which cannot be legally possessed, sold, or transported except for medicinal uses for which a physician or dentist's prescription is required. , which is considered today's standard of care. Results with the ON-Q therapy included lower pain scores, decreased need for narcotics and narcotic narcotic, any of a number of substances that have a depressant effect on the nervous system. The chief narcotic drugs are opium, its constituents morphine and codeine, and the morphine derivative heroin. See also drug addiction and drug abuse. intake, reduced narcotic side effects Side effects Effects of a proposed project on other parts of the firm. , higher patient satisfaction scores and a full day reduction in hospital length of stay. According to the meta-analysis principal researcher and lead author, Spencer S. Liu, MD, these results are potentially significant due to the growing physician interest and patient need for better practices for post-surgical pain relief. Dr. Liu, of the Hospital for Special Surgery and the Weill College of Medicine of Cornell University, stated, "Recent surveys have shown that current techniques for treating post-surgical pain have met with modest success. This can translate into uncontrolled pain uncontrolled pain Neurology Pain that doesn't respond to medications at doses that usually provide appropriate analgesia , resulting in a number of long-term negative outcomes." He continued by saying, "The results of this meta-analysis clearly identified continuous wound catheters delivering local anesthetic as providing improved pain relief, with consistent evidence of benefits across a wide range of surgical procedures. These findings coupled with the therapy's simplicity encourage both further investigation and increased clinical use." "I-Flow has been committed to providing better post-surgical pain relief to the millions of patients undergoing surgery every year by offering ON-Q PainBuster as a significantly better alternative to narcotics," noted Donald M. Earhart, I-Flow's Chairman, President and Chief Executive Officer. "We are excited that the benefits of ON-Q that we have been advocating have been recognized in a study of this magnitude with scientific evidence that led to the publication in the Journal of American College Surgeons. We believe that the positive results of this meta-analysis will help surgeons, hospitals, insurance companies, managed care providers and other allied health professionals to better understand how ON-Q redefines recovery and gets patients back to normal faster," he added. About ON-Q ON-Q is now labeled to significantly reduce pain better than narcotics and to significantly reduce narcotics intake after surgery. ON-Q is a simple yet elegant device that consists of a small balloon pump that holds a local anesthetic (a pain-numbing medicine) and delivers it automatically through a tiny, specially designed tube (catheter) to provide even distribution of local anesthetic over a wider area, as compared to other catheters, because of its patented wicking capabilities. Currently, more than 55 studies on the use of ON-Q have been completed and published or presented and more are underway to demonstrate the benefits of ON-Q in additional areas such as reduced infection risk, combination therapies (e.g., a local anesthetic and antibiotic mix, a combination of a local anesthetic and an anti-inflammatory), pediatrics and chronic pain. To learn more about the benefits of ON-Q visit www.AskYourSurgeon.com. About I-Flow I-Flow Corporation (www.IFLO.com) designs, develops and markets technically advanced, low cost drug delivery systems and services that are redefining the standard of care by providing life enhancing, cost effective solutions for pain relief. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement Certain disclosures made by the Company in this press release and in other reports and statements released by the Company are and will be forward looking in nature, such as comments that express the Company's opinions about trends and factors that may impact future operating results. Disclosures that use words such as the Company "believes", "anticipates", or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ from those expected, and readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to republish revised forward-looking statements to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this release, which seek to advise interested parties of the risks, and other factors that affect the Company's business, as well as in the Company's periodic reports on Forms 10-K, 10-Q and 8-K filed with the Securities and Exchange Commission. The risks affecting the Company's business include, among others: successful consummation of the previously announced sale of InfuSystem, Inc; physician acceptance of infusion-based therapeutic regimens; implementation of our direct sales strategy; dependence on our suppliers and distributors; reliance on the success of the home health care industry; our continuing compliance with applicable laws and regulations, such as the Food, Drug and Cosmetic Act Federal Food, Drug and Cosmetic Act a regulation in the United States which requires all drugs used in animals to be approved by the Food and Drug Administration. , and the FDA's concurrence CONCURRENCE, French law. The equality of rights, or privilege which several persons-have over the same thing; as, for example, the right which two judgment creditors, Whose judgments were rendered at the same time, have to be paid out of the proceeds of real estate bound by them. Dict. de Jur. h.t. with our management's subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; competition in the industry; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; technological changes; and product availability and acceptance. All forward-looking statements, whether made in this release or elsewhere, should be considered in context with the various disclosures made by the Company about its business. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion